NYMXF
Nymox Pharmaceutical Corporation
Price Chart
Latest Quote
$0.06
+0.03 (+96.33%)
Current Price
| Previous Close | $0.03 |
| Open | $0.02 |
| Day High | $0.03 |
| Day Low | $0.02 |
| Volume | 41,200 |
Stock Information
| Shares Outstanding | 105.04M |
| Total Debt | $3.29M |
| Cash Equivalents | $74K |
| Net Income | $-4.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.19M |
| EPS (TTM) | $-0.05 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.31M |
| Income | $-4.28M |
| Book/sh | $-0.09 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.06 |
Returns & Margins
| ROA | -373.68% |
Ownership
| Insider Ownership | 48.60% |
| Institutional Ownership | 0.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 2.29 |
| P/B | -0.65 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.04 |
| SMA50 | $0.03 |
| SMA200 | $0.05 |
| RSI | 62.58 |
| ATR | 0.0197 |
| Shares Float | 55.06M |
| Short Float | 4.65% |
| Short Ratio | 59.74 |
| Volatility | -6.51 |
| Rel Volume | 3.72 |
Performance History
| Week | -1.83% |
| Month | +84.06% |
| Quarter | +194.50% |
| 6 Months | -10.62% |
| YTD | +26.48% |
| Year | -44.95% |
| 3 Years | -94.11% |
| 5 Years | -96.92% |
| 10 Years | -98.14% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-30 | $0.06 | 52,815 |
| 2026-10-29 | $0.03 | 55,279 |
| 2026-10-28 | $0.03 | 7,725 |
| 2026-10-27 | $0.04 | 1,500 |
| 2026-10-26 | $0.04 | 7,500 |
| 2026-10-23 | $0.06 | 14,000 |
| 2026-10-22 | $0.06 | 36,000 |
| 2026-10-21 | $0.06 | 63,810 |
| 2026-10-20 | $0.03 | 6,805 |
| 2026-10-19 | $0.04 | 0 |
| 2026-10-16 | $0.04 | 1,279 |
| 2026-10-15 | $0.03 | 2,450 |
| 2026-10-14 | $0.03 | 0 |
| 2026-10-13 | $0.03 | 1,102 |
| 2026-10-12 | $0.03 | 0 |
| 2026-10-09 | $0.03 | 21,624 |
| 2026-10-08 | $0.03 | 0 |
| 2026-10-07 | $0.03 | 0 |
| 2026-10-06 | $0.03 | 0 |
| 2026-10-05 | $0.03 | 12,049 |
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
đ° Latest News
No news articles available at the moment. Check back later for updates on NYMXF.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | $0 | $0 | $0 |
| Cost Of Revenue | - | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $226,000 | $61,000 | $43,000 | $39,000 |
| Total Expenses | $4,283,000 | $8,350,000 | $6,652,000 | $12,504,000 |
| Other Income Expense | $15,000 | $-439,000 | $118,000 | $-2,000 |
| Net Non Operating Interest Income Expense | $-224,000 | $-55,000 | $-42,000 | $-31,000 |
| Interest Expense Non Operating | $226,000 | $61,000 | $43,000 | $39,000 |
| Operating Expense | $4,283,000 | $8,350,000 | $6,652,000 | $12,504,000 |
| General And Administrative Expense | $1,003,000 | $4,356,000 | $2,879,000 | $5,846,000 |
| Other Non Operating Income Expenses | - | - | $113,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Net Interest Income | $-224,000 | $-55,000 | $-42,000 | $-31,000 |
| Interest Income | $2,000 | $6,000 | $1,000 | $8,000 |
| Normalized Income | $-4,507,000 | $-8,405,000 | $-6,581,000 | $-12,535,000 |
| Net Income From Continuing And Discontinued Operation | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Total Operating Income As Reported | $-4,283,000 | $-8,350,000 | $-6,652,000 | $-12,504,000 |
| Net Income Common Stockholders | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Net Income | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Net Income Including Noncontrolling Interests | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Net Income Continuous Operations | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Pretax Income | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Interest Income Non Operating | $2,000 | $6,000 | $1,000 | $8,000 |
| Operating Income | $-4,283,000 | $-8,350,000 | $-6,652,000 | $-12,504,000 |
| Special Income Charges | - | $-440,000 | - | - |
| Gross Profit | - | $0 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.05 | $-0.10 | $-0.07 | $-0.15 |
| Basic EPS | $-0.05 | $-0.10 | $-0.07 | $-0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,280,000 | $-8,175,000 | $-6,289,000 | $-12,242,000 |
| Total Unusual Items | $15,000 | $-439,000 | $5,000 | $-2,000 |
| Total Unusual Items Excluding Goodwill | $15,000 | $-439,000 | $5,000 | $-2,000 |
| Reconciled Depreciation | $1,000 | $169,000 | $249,000 | $254,000 |
| EBITDA (Bullshit earnings) | $-4,265,000 | $-8,614,000 | $-6,284,000 | $-12,244,000 |
| EBIT | $-4,266,000 | $-8,783,000 | $-6,533,000 | $-12,498,000 |
| Diluted Average Shares | $93,671,288 | $91,687,400 | $89,382,603 | $81,976,000 |
| Basic Average Shares | $93,671,288 | $91,687,400 | $89,382,603 | $81,976,000 |
| Diluted NI Availto Com Stockholders | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $15,000 | $1,000 | $5,000 | $-2,000 |
| Research And Development | $3,280,000 | $3,994,000 | $3,773,000 | $6,658,000 |
| Selling General And Administration | $1,003,000 | $4,356,000 | $2,879,000 | $5,846,000 |
| Other Gand A | $1,003,000 | $4,356,000 | $2,879,000 | $5,846,000 |
| Other Special Charges | - | $440,000 | - | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,775,000 | $-3,173,000 | $-482,000 | $-506,000 |
| Total Assets | $654,000 | $627,000 | $1,625,000 | $1,443,000 |
| Total Non Current Assets | $1,000 | $2,000 | $168,000 | $406,000 |
| Current Assets | $653,000 | $625,000 | $1,457,000 | $1,037,000 |
| Prepaid Assets | $552,000 | $544,000 | $44,000 | $28,000 |
| Receivables | $27,000 | $11,000 | $10,000 | $13,000 |
| Other Receivables | $27,000 | $11,000 | $10,000 | $13,000 |
| Cash Cash Equivalents And Short Term Investments | $74,000 | $70,000 | $1,403,000 | $830,000 |
| Cash And Cash Equivalents | $74,000 | $70,000 | $1,403,000 | $830,000 |
| Cash Financial | $74,000 | $70,000 | $1,403,000 | $830,000 |
| Other Current Assets | - | - | $16,000 | $132,000 |
| Inventory | - | - | $0 | $34,000 |
| Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $0 | $0 | $173,000 | $391,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $163,000 |
| Current Debt And Capital Lease Obligation | - | - | $173,000 | $228,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,429,000 | $3,800,000 | $2,107,000 | $1,949,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $163,000 |
| Current Liabilities | $7,429,000 | $3,800,000 | $2,107,000 | $1,786,000 |
| Current Deferred Liabilities | $3,286,000 | $750,000 | $0 | - |
| Payables And Accrued Expenses | $4,143,000 | $3,050,000 | $1,934,000 | $1,558,000 |
| Payables | $4,115,000 | $3,023,000 | $1,697,000 | $1,273,000 |
| Accounts Payable | $4,115,000 | $3,023,000 | $1,697,000 | $1,273,000 |
| Equity | ||||
| Common Stock Equity | $-6,775,000 | $-3,173,000 | $-482,000 | $-506,000 |
| Total Equity Gross Minority Interest | $-6,775,000 | $-3,173,000 | $-482,000 | $-506,000 |
| Stockholders Equity | $-6,775,000 | $-3,173,000 | $-482,000 | $-506,000 |
| Retained Earnings | $-212,474,000 | $-207,982,000 | $-199,138,000 | $-192,562,000 |
| Other Equity Interest | - | - | - | $-589,000 |
| Other | ||||
| Ordinary Shares Number | $94,540,140 | $93,540,140 | $90,515,140 | $85,545,875 |
| Share Issued | $94,540,140 | $93,540,140 | $90,515,140 | $85,545,875 |
| Tangible Book Value | $-6,775,000 | $-3,173,000 | $-482,000 | $-506,000 |
| Invested Capital | $-6,775,000 | $-3,173,000 | $-482,000 | $-506,000 |
| Working Capital | $-6,776,000 | $-3,175,000 | $-650,000 | $-749,000 |
| Capital Lease Obligations | $0 | $0 | $173,000 | $391,000 |
| Total Capitalization | $-6,775,000 | $-3,173,000 | $-482,000 | $-506,000 |
| Additional Paid In Capital | $28,012,000 | $27,784,000 | $26,985,000 | $27,584,000 |
| Capital Stock | $177,687,000 | $177,025,000 | $171,671,000 | $165,061,000 |
| Common Stock | $177,687,000 | $177,025,000 | $171,671,000 | $165,061,000 |
| Current Capital Lease Obligation | $0 | $0 | $173,000 | $228,000 |
| Current Accrued Expenses | $28,000 | $27,000 | $237,000 | $285,000 |
| Net PPE | $1,000 | $2,000 | $168,000 | $406,000 |
| Accumulated Depreciation | $-595,000 | $-594,000 | $-583,000 | $-571,000 |
| Gross PPE | $596,000 | $596,000 | $751,000 | $977,000 |
| Other Properties | $418,000 | $418,000 | $576,000 | $802,000 |
| Machinery Furniture Equipment | $178,000 | $178,000 | $175,000 | $175,000 |
| Long Term Capital Lease Obligation | - | - | $0 | $163,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,601,000 | $-4,060,000 | $-5,205,000 | $-9,826,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,601,000 | $-4,057,000 | $-5,205,000 | $-9,820,000 |
| Cash Flow From Continuing Operating Activities | $-2,601,000 | $-4,057,000 | $-5,205,000 | $-9,820,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-3,000 | $0 | $-6,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-3,000 | $0 | $-6,000 |
| Capital Expenditure | - | $-3,000 | - | $-6,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $1,150,000 | $6,007,000 | $7,283,000 |
| Financing Cash Flow | $2,605,000 | $2,727,000 | $5,778,000 | $7,045,000 |
| Cash Flow From Continuing Financing Activities | $2,605,000 | $2,727,000 | $5,778,000 | $7,045,000 |
| Net Common Stock Issuance | $0 | $1,150,000 | $6,007,000 | $7,283,000 |
| Common Stock Issuance | $0 | $1,150,000 | $6,007,000 | $7,283,000 |
| Other | ||||
| Repayment Of Debt | $-64,000 | $-173,000 | $-229,000 | $-238,000 |
| Issuance Of Debt | $2,669,000 | $1,750,000 | - | - |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $74,000 | $70,000 | $1,403,000 | $830,000 |
| Beginning Cash Position | $70,000 | $1,403,000 | $830,000 | $3,611,000 |
| Changes In Cash | $4,000 | $-1,333,000 | $573,000 | $-2,781,000 |
| Net Issuance Payments Of Debt | $2,605,000 | $1,577,000 | $-229,000 | $-238,000 |
| Net Short Term Debt Issuance | $2,669,000 | $1,750,000 | - | - |
| Short Term Debt Issuance | $2,669,000 | $1,750,000 | - | - |
| Net Long Term Debt Issuance | $-64,000 | $-173,000 | $-229,000 | $-238,000 |
| Long Term Debt Payments | $-64,000 | $-173,000 | $-229,000 | $-238,000 |
| Net PPE Purchase And Sale | $0 | $-3,000 | $0 | $-6,000 |
| Purchase Of PPE | $0 | $-3,000 | $0 | $-6,000 |
| Change In Working Capital | $1,219,000 | $821,000 | $495,000 | $-140,000 |
| Change In Payables And Accrued Expense | $1,243,000 | $1,322,000 | $376,000 | $-165,000 |
| Change In Prepaid Assets | $-8,000 | $-500,000 | $116,000 | $18,000 |
| Change In Receivables | $-16,000 | $-1,000 | $3,000 | $7,000 |
| Stock Based Compensation | $671,000 | $3,357,000 | $593,000 | $2,603,000 |
| Asset Impairment Charge | $0 | $0 | $34,000 | - |
| Depreciation Amortization Depletion | $1,000 | $169,000 | $249,000 | $254,000 |
| Depreciation And Amortization | $1,000 | $169,000 | $249,000 | $254,000 |
| Amortization Cash Flow | $0 | $158,000 | $237,000 | $242,000 |
| Amortization Of Intangibles | $0 | $158,000 | $237,000 | $242,000 |
| Depreciation | $1,000 | $11,000 | $12,000 | $12,000 |
| Net Income From Continuing Operations | $-4,492,000 | $-8,844,000 | $-6,576,000 | $-12,537,000 |
| Other Non Cash Items | - | $440,000 | - | - |
| Change In Inventory | - | - | $0 | $0 |
Fetched: 2026-02-02